The DaVita-Fresenius Duopoly: What Dialysis Patients Need to Know

Two companies control approximately two-thirds of the roughly 6,700 dialysis facilities in the United States. DaVita and Fresenius Medical Care together account for about 90% of the industry's $25 billion in annual revenue. For the roughly 500,000 Americans who depend on dialysis to stay alive, this level of market concentration has direct consequences.

The scale of the problem

The dialysis industry is among the most concentrated sectors of the American economy. When you walk into a dialysis clinic in most American cities, there is roughly a two-in-three chance it is owned by DaVita or Fresenius. In some markets, one of these companies operates every available option within a reasonable driving distance.

This concentration did not happen by accident. Both companies have pursued aggressive acquisition strategies over the past two decades, buying up independent clinics across the country. As of 2025, there are fewer independent dialysis providers than at any point in the industry's history.

What the research shows

Peer-reviewed studies published in JAMA in 2025 examined what happens when DaVita or Fresenius acquires an independent dialysis clinic. The findings were consistent:

• Transplant referrals dropped by approximately 10% after acquisition
• Patient survival rates declined
• Hospitalization rates increased
• Infection rates rose

The financial logic is straightforward. A dialysis patient generates recurring revenue three times a week, every week, for years. A successful kidney transplant ends that revenue stream permanently. The data suggests that when profit-maximizing chains take over independent clinics, patient care shifts in ways that are financially favorable for the company but medically unfavorable for patients.

The regulatory response

The pattern has drawn attention from multiple directions:

• The FTC opened a probe into DaVita and Fresenius over noncompete agreements that trap physicians in referral relationships
• The US Senate has conducted investigations into the industry's market concentration
• CBS News has produced investigative reports on the duopoly's impact on patient care
• Collectively, DaVita and Fresenius have paid over $1 billion in settlements and fines over the past decade

Both companies have characterized these payments as ordinary costs of doing business in a heavily regulated industry.

What you can do

As a dialysis patient, you have the right to know who owns your clinic and how it performs on the government's quality metrics. CMS publishes star ratings, patient survival data, infection rates, and transplant referral percentages for every Medicare-certified dialysis facility in the country.

Use this data to:

1. Check your clinic's star rating and compare it to others in your area
2. Look at transplant referral rates — if your clinic's rate is significantly below the national average, ask your nephrologist why
3. Compare chain-owned vs independent clinics in your area on infection rates and patient survival
4. Ask about home dialysis options, which give you more control over your treatment and are not tied to a specific clinic's chair schedule

The CMS data is public and free. That is exactly why we built DialysisCenterUSA — to make it easy to find, read, and compare.